What is DF/HCC?
Dana-Farber/Harvard Cancer Center (DF/HCC) is an NCI-designated comprehensive cancer center that unites the cancer research efforts of five Boston academic medical institutions—Beth Israel Deaconess Medical Center, Boston Children’s Hospital, Brigham and Women’s Hospital, Dana-Farber Cancer Institute, and Massachusetts General Hospital—and two Harvard Schools—the Harvard Medical School and the Harvard T.H. Chan School of Public Health.
Am I a part of DF/HCC?
- Does your work involve research activities including, but not limited to the design, coordination, conduct, oversight or research administration of cancer-relevant research?
- Are you employed at one of the member institutions listed above (BCH, BIDMC, BWH, DFCI, HMS, HSPH, MGH)?
If you answered yes to both questions, then you are a part of DF/HCC!
Do I need to submit my research to DF/HCC?
All studies conducted under DF/HCC must be submitted for centralized review and reporting. (This applies to all studies, whether reviewed by the DFCI IRB or an external single IRB)
Unsure whether your research project must be submitted to DF/HCC? Review the following for guidance:
- DF/HCC Protocol Review Requirements (guidance document)
- What types of Research Require Submission to DF/HCC and Why? (8 minute e-learning)
I am required to submit my research to DF/HCC - what does that mean?
Applicable research projects are subject to DF/HCC policies and must comply with DF/HCC requirements, including the following:
- You must submit your new project through the iRIS system to facilitate DF/HCC review and approval
- Visit the New Protocol Submissions page for guidance on how to submit a new project
- Visit the New Protocol Submissions page for guidance on how to submit a new project
- Anyone working on DF/HCC research must comply with specific training requirements
- View the DF/HCC Education and Training page for additional guidance on completing required training
Note - There may be additional institution-specific requirements and processes that also apply. Contact your institutional clinical trials office for guidance.